TCT 2009 schedule

Here is the page we will use to coordinate the TV events at TCT 2009.

---

Click on Date for Detailed Schedule

Monday September 21, 2009

Tuesday September 22, 2009

Wednesday September 23, 2009

Thursday September 24, 2009

Friday September 25, 2009

---

Monday September 21, 2009

1:05 PM

1:05 PM - 1:15 PM

• Event: The Drug-Eluting Stent Summit Part 1: Appropriate Utilization of Current Generation Devices. Session III. DES Safety Considerations
• Room: 104

1:51 PM

1:51 PM - 2:03 PM

• Event: The Drug-Eluting Stent Summit Part 1: Appropriate Utilization of Current Generation Devices. Session III. DES Safety Considerations
• Room: 104

Return to top

Tuesday September 22, 2009

10:00 AM

10:00 AM - 12:00 PM

• Event: Oral Abstracts- AMI
• Room: 125

12:30 PM

12:30 PM - 1:00 PM

• Event: Interview
• Room: East 264
• Interviewee: Pieter C. Smits
• Trial: COMPARE. A Prospective, Randomized Trial of Everolimus-eluting vs. Paclitaxel-Eluting Stents
• Phone number:

1:00 PM

1:00 PM - 1:30 PM

• Event: Interview
• Room: East 264
• Interviewee: Shamir Mehta
• Trial: CURRENT-PCI OASIS 7. A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS
• Phone number:

2:00 PM

2:00 PM - 2:30 PM

• Event: Interview
• Room: East 264
• Interviewee: John Spertus
• Trial: NEVO RES-ELUTION I QOL: Formal Quality-of-Life Assessment from a Prospective Trial of a Novel Sirolimus-Eluting Stent and a Paclitaxel-Eluting Stent
• Phone number:

2:30 PM

2:30 PM - 3:00 PM

• Event: Interview
• Room: East 264
• Interviewee: Eberhard Grube
• Trial: BIOFREEDOM: A Prospective Randomized Trial of a Polymer-Free Biolimus A9-Eluting Stent
• Phone number:

3:00 PM

3:00 PM - 3:30 PM

• Event: Interview
• Room: East 264
• Interviewee: David Allie
• Trial: CROSS-CLI: A Prospective Multicenter Registry of Ultrasound-Facilitated Recanalization of Peripheral Chronic Total Occlusions
• Phone number:

3:30 PM

3:30 PM - 4:00 PM

• Event: Interview
• Room: East 264
• Interviewee: Douglas Losordo
• Trial: ACT34-CMI: One-Year Results from a Prospective, Randomized, Placebo-Controlled Phase II Trial of CD34+ Cells in Patients with Refractory Angina
• Phone number:

4:00 PM

4:00 PM - 4:30 PM

• Event: Interview
• Room: East 264
• Interviewee: Gary Ansel
• Trial: ARMOUR: A Prospective, Nonrandomized Study of the Mo.Ma Proximal Cerebral Protection Device in High Surgical Risk Subjects Undergoing Carotid Artery Stenting
• Phone number:

4:30 PM

4:30 PM - 5:00 PM

• Event: Interview
• Room: East 264
• Interviewee: Ran Kornowski
• Trial:
• Phone number:

Return to top

Wednesday September 23, 2009

8:30 AM

8:30 AM - 9:00 AM

• Event: Interview
• Room: East 264
• Interviewee: William Fearon
• Confirmed: Yes
• Trial: FAME: 2-Year Follow-up From a Prospective, Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease
• Phone number:

9:00 AM

9:00 AM - 9:30 AM

• Event: Interview
• Room: East 264
• Interviewee: Lorenz Raber
• Confirmed: Yes
• Trial: SIRTAX-LATE. 5-Year Clinical and Angiographic Follow-up from a Prospective, Randomized Trial of Sirolimus-Eluting and Paclitaxel-Eluting Stents
• Phone number:

9:30 AM

9:30 AM - 10:00 AM

• Event: Interview
• Room: East 264
• Interviewee: Volker Klauss
• Confirmed: Yes
• Trial: LEADERS. 2-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer
• Phone number:

10:00 AM

10:00 AM - 10:30 AM

• Event: Interview
• Room: East 264
• Interviewee: Deepak Bhatt
• Confirmed: Yes
• Trial: 1) COGENT. A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel

2) CHARISMA GENOMICS SUBSTUDY. Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention

• Phone number:

10:30 AM

10:30 AM - 11:00 AM

• Event: Interview
• Room: East 264
• Interviewee: David Cohen
• Confirmed: Yes
• Trial: TRITON-TIMI 38 ECONOMIC SUBSTUDY. Cost-Effectiveness of Prasugrel vs. Clopidogrel From a Prospective, Randomized Trial of Patients with ACS Undergoing PCI
• Phone number:

11:00 AM

11:00 AM - 11:30 AM

• Event: Interview
• Room: East 264
• Interviewee: Chris Cannon
• Confirmed: Yes
• Trial: PLATO INVASIVE. A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy
• Phone number:

12:00 PM

12:00 PM - 12:30 PM

• Event: Interview
• Room: East 264
• Interviewee: Robert Byrne
• Confirmed: Yes
• Trial: ISAR-DESIRE 2. A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Restenosis in Sirolimus-Eluting Stents
• Phone number:

12:45 PM

12:45 PM - 12:50 PM

• Event: Open Issues I: Adjunct Pharmacology. Schedule
• Room: 130

1:35 PM

1:35 PM - 1:45 PM

• Event: Open Issues I: Adjunct Pharmacology. Schedule
• Room: 130

4:00 PM

4:00 PM - 4:45 PM

• Event: Main Arena I. Plenary Session #7 Personalized Clinical Decision-Making Case Study: The Ischemia vs. Bleeding Controversy
• Room: Esplanade Ballroom

Return to top

Thursday September 24, 2009

8:46 AM

8:46 AM - 11:11 AM

• Event: Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Anti-Thrombins, Xa Inhibitors and Emerging Agents. Session 2: Current Choices in Antithrombin Therapy for ACS and PCI
• Room: 135

11:45 PM

11:45 AM - 11:57 AM

• Event: Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Anti-Thrombins, Xa Inhibitors and Emerging Agents. Session 3: Emerging Alternatives for Antiocoagulation for ACS and PCI
• Room: 135

12:09 PM

12:09 PM - 12:24 PM

• Event: Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Anti-Thrombins, Xa Inhibitors and Emerging Agents. Session 3: Emerging Alternatives for Antiocoagulation for ACS and PCI
• Room: 135

12:45 PM

12:45 PM - 1:15 PM

• Event: Interview
• Room: East 264
• Interviewee: Cheol Whan Lee
• Trial: 1) ZEST: Final Angiographic and IVUS Results From a Large-Scale Randomized Trial of Zotarolimus-Eluting, Sirolimus-Eluting and Paclitaxel-Eluting Stents; 2) CILOTAX: A Prospective, Randomized, Controlled Trial of a Stent Eluting Cilostazol and Paclitaxel
• Phone number:

1:15 PM

1:15 PM - 1:45 PM

• Event: Interview
• Room: East 264
• Interviewee: Flavio Ribichini
• Trial: CEREA-DES: A Prospective Randomized Trial of Corticosteroids in Patients Undergoing Stent Implantation
• Phone number:

1:45 PM

1:45 PM - 2:15 PM

• Event: Interview
• Room: East 264
• Interviewee: Josef Veselka
• Trial: STATINS PRE-PCI: A Prospective Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina
• Phone number:

2:15 PM

2:15 PM - 2:45 PM

• Event: Interview
• Room: East 264
• Interviewee: Patrick Ohlmann
• Trial: MISTRAL: A Prospective Randomized Trial of Ambulance-Initiated vs. Cath Lab-Initiated Intravenous Abciximab in Patients with STEMI
• Phone number:

2:45 PM

2:45 PM - 3:15 PM

• Event: Interview
• Room: East 264
• Interviewee: Junbo Ge
• Trial: NO REFLOW: A Prospective Randomized Trial of Intracoronary vs. Guide Catheter Infusion of Nitrates vs. Calcium Channel Blockers in Patients with No Reflow After Primary PCI in STEMI
• Phone number:

3:15 PM

3:15 PM - 3:45 PM

• Event: Interview
• Room: East 264
• Interviewee: Giulio Guagliumi
• Trial: OCTAMI: A Prospective Randomized Trial of Zotarolimus-Eluting and Bare-Metal Stents in STEMI Assessed by OCT
• Phone number:

3:45 PM

3:45 PM - 4:15 PM

• Event: Interview
• Room: East 264
• Interviewee: Josep Rodes-Cabau
• Trial: The Canadian Transcatheter Aortic Valve Implantation Program: Acute and Late Follow-up from a Multicenter Consecutive Series of Patients with Inoperable or High-Surgical Risk Aortic Stenosis
• Phone number:

4:15 PM

4:15 PM - 4:45 PM

• Event: Interview
• Room: East 264
• Interviewee: Dirk Walter
• Trial: PROVASA: A Prospective, Randomized, Placebo-Controlled Trial of Intra-Arterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells in Patients with Peripheral Arterial Occlusive Disease
• Phone number:

5:02 PM

5:02 PM - 5:14 PM

• Event: Balancing Safety and Efficacy of Antithrombotic Therapies for PCI and ACS. Antiplatelet Agents, Bleeding, and Ischemia
• Room: 135

Return to top

Friday September 25, 2009

10:30 AM

10:30 AM - 11:00 AM

• Event: Interview
• Room: East 264
• Interviewee: Simon Redwood
• Confirmed: Yes
• Trial: BCIS-1. A Prospective, Randomized Trial of Intraaortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI
• Phone number:

11:00 AM

11:00 AM - 11:30 AM

• Event: Interview
• Room: East 264
• Interviewee: Arnold Seto
• Confirmed: Yes
• Trial: FAUST. A Prospective, Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access
• Phone number:

12:30 PM

12:30 PM - 1:00 PM

• Event: Interview
• Room: East 264
• Interviewee: Rolf Michels
• Confirmed: Yes
• Trial: DEBATER. A Prospective, Randomized Trial of Drug-Eluting vs. Bare Metal Stents With or Without Abciximab in STEMI
• Phone number:

1:00 PM

1:00 PM - 1:30 PM

• Event: Interview
• Room: East 264
• Interviewee: Gregg Stone
• Confirmed: Yes
• Trial: 1) SPIRIT IV. A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

2) PROSPECT. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque, 3) HORIZONS-AMI. 2-Year Follow-up From a Prospective, Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare Metal Stents in STEMI

• Phone number:

1:30 PM

1:30 PM - 2:00 PM

• Event: Interview
• Room: East 264
• Interviewee: Henry Krum
• Confirmed: Yes
• Trial: SYMPLICITY I. 1-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension
• Phone number:

2:24 PM

2:24 PM - 2:36 PM

• Event: Top Interventional Trials of the Last Year: Perspectives from the Experts

GPIIb/IIIa Inhibitors in ACS: EARLY ACS

• Room: EBM and Guidelines Theater, Hall D

2:36 PM

2:36 PM - 3:12 PM

• Event: Top Interventional Trials of the Last Year: Perspectives from the Experts

Aspirin and Clopiodgrel in ACS: CURRENT-OASIS 7

• Room: EBM and Guidelines Theater, Hall D

3:00 PM

3:00 PM - 3:12 PM

• Event: Top Interventional Trials of the Last Year: Perspectives from the Experts

Aspirin and Clopiodgrel in ACS: CURRENT-OASIS 7

• Room: EBM and Guidelines Theater, Hall D

3:24 PM

3:24 PM - 3:36 PM

• Event: Top Interventional Trials of the Last Year: Perspectives from the Experts

Ticagrelor in ACS: PLATO

• Room: EBM and Guidelines Theater, Hall D

3:36 PM

3:36 PM - 3:48 PM

• Event: Top Interventional Trials of the Last Year: Perspectives from the Experts

Ticagrelor in ACS: PLATO

• Room: EBM and Guidelines Theater, Hall D

Return to top